ES2895256T3 - Polipéptidos para inhibir la activación del complemento - Google Patents
Polipéptidos para inhibir la activación del complemento Download PDFInfo
- Publication number
- ES2895256T3 ES2895256T3 ES16828743T ES16828743T ES2895256T3 ES 2895256 T3 ES2895256 T3 ES 2895256T3 ES 16828743 T ES16828743 T ES 16828743T ES 16828743 T ES16828743 T ES 16828743T ES 2895256 T3 ES2895256 T3 ES 2895256T3
- Authority
- ES
- Spain
- Prior art keywords
- polypeptide
- complement
- fhr1
- mfhr1
- scr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 52
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 48
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 48
- 230000024203 complement activation Effects 0.000 title description 37
- 108010053085 Complement Factor H Proteins 0.000 claims abstract description 68
- 102000016550 Complement Factor H Human genes 0.000 claims abstract description 68
- 108010071253 factor H-related protein 1 Proteins 0.000 claims abstract description 55
- 210000004027 cell Anatomy 0.000 claims abstract description 39
- 230000027455 binding Effects 0.000 claims abstract description 27
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 claims abstract description 13
- 101150105073 SCR1 gene Proteins 0.000 claims abstract description 13
- 101100134054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NTG1 gene Proteins 0.000 claims abstract description 13
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 claims abstract description 9
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 claims abstract description 9
- 150000001413 amino acids Chemical class 0.000 claims description 36
- 208000029574 C3 glomerulopathy Diseases 0.000 claims description 26
- 208000027134 non-immunoglobulin-mediated membranoproliferative glomerulonephritis Diseases 0.000 claims description 26
- 230000015572 biosynthetic process Effects 0.000 claims description 25
- 230000002401 inhibitory effect Effects 0.000 claims description 24
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims description 21
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 13
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 13
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 9
- 208000002780 macular degeneration Diseases 0.000 claims description 9
- 238000006471 dimerization reaction Methods 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000004154 complement system Effects 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 4
- 206010021263 IgA nephropathy Diseases 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 108010074405 complement C5b-6 complex Proteins 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 230000008736 traumatic injury Effects 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 68
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 68
- 102100022133 Complement C3 Human genes 0.000 description 51
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 51
- 239000012636 effector Substances 0.000 description 33
- 230000000295 complement effect Effects 0.000 description 28
- 230000004913 activation Effects 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 24
- 229960002224 eculizumab Drugs 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 102100035326 Complement factor H-related protein 2 Human genes 0.000 description 19
- 101000878135 Homo sapiens Complement factor H-related protein 2 Proteins 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 238000003776 cleavage reaction Methods 0.000 description 18
- 230000001105 regulatory effect Effects 0.000 description 18
- 230000007017 scission Effects 0.000 description 18
- 108090000056 Complement factor B Proteins 0.000 description 15
- 102100035325 Complement factor H-related protein 5 Human genes 0.000 description 14
- 101000878134 Homo sapiens Complement factor H-related protein 5 Proteins 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 13
- 102000003712 Complement factor B Human genes 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 230000021917 activation of membrane attack complex Effects 0.000 description 10
- 229940098773 bovine serum albumin Drugs 0.000 description 10
- 206010018910 Haemolysis Diseases 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000008588 hemolysis Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000000151 deposition Methods 0.000 description 8
- 230000008021 deposition Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000001434 glomerular Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 description 5
- 108010089414 Anaphylatoxins Proteins 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 108010027437 compstatin Proteins 0.000 description 5
- 230000008482 dysregulation Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108090000955 Complement C2 Proteins 0.000 description 4
- 102100034622 Complement factor B Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 102100039373 Membrane cofactor protein Human genes 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 102100022002 CD59 glycoprotein Human genes 0.000 description 3
- 101710172562 Cobra venom factor Proteins 0.000 description 3
- 102100030886 Complement receptor type 1 Human genes 0.000 description 3
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000585 glomerular basement membrane Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000004023 fresh frozen plasma Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- YTPUIQCGRWDPTM-UHFFFAOYSA-N 2-acetyloxybenzoic acid;5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O YTPUIQCGRWDPTM-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 101100390700 Arabidopsis thaliana FH20 gene Proteins 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 108010055167 CD59 Antigens Proteins 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 108010078015 Complement C3b Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 102100035321 Complement factor H-related protein 3 Human genes 0.000 description 1
- 102100035324 Complement factor H-related protein 4 Human genes 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100440311 Homo sapiens C5 gene Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000878136 Homo sapiens Complement factor H-related protein 3 Proteins 0.000 description 1
- 101000878133 Homo sapiens Complement factor H-related protein 4 Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101710146216 Membrane cofactor protein Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000034762 Meningococcal Infections Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000195888 Physcomitrella Species 0.000 description 1
- 241000195887 Physcomitrella patens Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101150039984 RCA gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000001707 glomerular endothelial cell Anatomy 0.000 description 1
- -1 hFH Proteins 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000011102 hetero oligomerization reaction Methods 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102015016665 | 2015-12-23 | ||
| PCT/EP2016/082614 WO2017109208A1 (en) | 2015-12-23 | 2016-12-23 | Polypeptides for inhibiting complement activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2895256T3 true ES2895256T3 (es) | 2022-02-18 |
Family
ID=57838331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16828743T Active ES2895256T3 (es) | 2015-12-23 | 2016-12-23 | Polipéptidos para inhibir la activación del complemento |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10640540B2 (pt) |
| EP (1) | EP3394089B1 (pt) |
| JP (2) | JP6771568B2 (pt) |
| KR (1) | KR20180091097A (pt) |
| CN (1) | CN108699121B (pt) |
| AU (1) | AU2016375183B2 (pt) |
| BR (1) | BR112018012844A2 (pt) |
| CA (1) | CA3009393C (pt) |
| DK (1) | DK3394089T3 (pt) |
| ES (1) | ES2895256T3 (pt) |
| HR (1) | HRP20211608T1 (pt) |
| HU (1) | HUE056019T2 (pt) |
| IL (1) | IL260182B2 (pt) |
| LT (1) | LT3394089T (pt) |
| MX (1) | MX2018007392A (pt) |
| PL (1) | PL3394089T3 (pt) |
| PT (1) | PT3394089T (pt) |
| SI (1) | SI3394089T1 (pt) |
| WO (1) | WO2017109208A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117338781A (zh) * | 2017-08-31 | 2024-01-05 | 诺华股份有限公司 | 哌啶基-吲哚衍生物的用途 |
| US20200262879A1 (en) | 2017-09-11 | 2020-08-20 | Insideoutbio, Inc. | Methods and compositions to enhance the immunogenicity of tumors |
| US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| EP3586860A1 (en) * | 2018-06-22 | 2020-01-01 | Universität Ulm | Complement inhibitors and uses thereof |
| DE102018120016B4 (de) * | 2018-08-16 | 2020-09-03 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- | Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0097440B1 (en) * | 1982-06-14 | 1986-09-24 | The Upjohn Company | Method and kit for removing and assaying complement system fragments |
| US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| ZA200807620B (en) * | 2006-03-08 | 2009-12-30 | Archemix Corp | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
| AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| CL2008003241A1 (es) | 2007-11-02 | 2009-07-31 | Novartis Ag | Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares |
| NZ614351A (en) | 2008-11-10 | 2015-05-29 | Alexion Pharma Inc | Methods and compositions for treating complement-associated disorders |
| JP5740772B2 (ja) * | 2009-08-31 | 2015-07-01 | アイビーシー ファーマスーティカルズ，インコーポレイテッド | 二重特異性免疫サイトカインドック−アンド−ロック（ｄｎｌ）複合体及びその治療的使用 |
| WO2011156356A1 (en) * | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
| NZ709997A (en) | 2011-04-08 | 2016-03-31 | Univ Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| CN102978204B (zh) * | 2011-11-11 | 2018-06-08 | 张康 | Cfhr1基因型、高密度脂蛋白上cfhr1及氧化磷酸胆碱的测定试剂盒及测定方法 |
| WO2013142362A1 (en) * | 2012-03-19 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Regulator of complement activation and uses thereof |
| FR3015484A1 (fr) * | 2013-12-20 | 2015-06-26 | Lab Francais Du Fractionnement | Proteines recombinantes possedant une activite de facteur h |
| WO2020041644A1 (en) * | 2018-08-22 | 2020-02-27 | Alexion Pharmaceuticals, Inc. | Fusion proteins and methods of treating complement dysregulation using the same |
| GB2583560A (en) * | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| WO2020232319A1 (en) * | 2019-05-15 | 2020-11-19 | Insideoutbio, Inc. | Modular therapeutics for the treatment of inflammatory diseases and cancer |
| WO2021247487A1 (en) * | 2020-06-01 | 2021-12-09 | Medical University Of South Carolina | Recombinant fusion proteins targeting p-selectin, and methods of use thereof for treating diseases and disorders |
-
2016
- 2016-12-23 MX MX2018007392A patent/MX2018007392A/es unknown
- 2016-12-23 HR HRP20211608TT patent/HRP20211608T1/hr unknown
- 2016-12-23 AU AU2016375183A patent/AU2016375183B2/en active Active
- 2016-12-23 PL PL16828743T patent/PL3394089T3/pl unknown
- 2016-12-23 CA CA3009393A patent/CA3009393C/en active Active
- 2016-12-23 BR BR112018012844A patent/BR112018012844A2/pt active Search and Examination
- 2016-12-23 DK DK16828743.1T patent/DK3394089T3/da active
- 2016-12-23 EP EP16828743.1A patent/EP3394089B1/en active Active
- 2016-12-23 KR KR1020187020929A patent/KR20180091097A/ko not_active Application Discontinuation
- 2016-12-23 CN CN201680075659.0A patent/CN108699121B/zh active Active
- 2016-12-23 HU HUE16828743A patent/HUE056019T2/hu unknown
- 2016-12-23 WO PCT/EP2016/082614 patent/WO2017109208A1/en active Application Filing
- 2016-12-23 LT LTEPPCT/EP2016/082614T patent/LT3394089T/lt unknown
- 2016-12-23 PT PT168287431T patent/PT3394089T/pt unknown
- 2016-12-23 IL IL260182A patent/IL260182B2/en unknown
- 2016-12-23 ES ES16828743T patent/ES2895256T3/es active Active
- 2016-12-23 SI SI201631377T patent/SI3394089T1/sl unknown
- 2016-12-23 US US16/065,272 patent/US10640540B2/en active Active
- 2016-12-23 JP JP2018533148A patent/JP6771568B2/ja active Active
-
2020
- 2020-03-20 US US16/825,711 patent/US11591378B2/en active Active
- 2020-05-01 JP JP2020081070A patent/JP2020167999A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20190300589A1 (en) | 2019-10-03 |
| IL260182B2 (en) | 2023-12-01 |
| JP2020167999A (ja) | 2020-10-15 |
| US20200277347A1 (en) | 2020-09-03 |
| CA3009393C (en) | 2023-08-22 |
| AU2016375183A1 (en) | 2018-07-19 |
| JP2019508022A (ja) | 2019-03-28 |
| KR20180091097A (ko) | 2018-08-14 |
| DK3394089T3 (da) | 2021-11-01 |
| HRP20211608T1 (hr) | 2022-01-21 |
| LT3394089T (lt) | 2021-11-25 |
| US10640540B2 (en) | 2020-05-05 |
| IL260182A (en) | 2018-07-31 |
| MX2018007392A (es) | 2018-08-15 |
| WO2017109208A1 (en) | 2017-06-29 |
| PT3394089T (pt) | 2021-11-03 |
| CA3009393A1 (en) | 2017-06-29 |
| EP3394089A1 (en) | 2018-10-31 |
| SI3394089T1 (sl) | 2021-12-31 |
| BR112018012844A2 (pt) | 2018-12-04 |
| EP3394089B1 (en) | 2021-07-28 |
| AU2016375183B2 (en) | 2021-01-21 |
| CN108699121B (zh) | 2023-07-04 |
| CN108699121A (zh) | 2018-10-23 |
| US11591378B2 (en) | 2023-02-28 |
| HUE056019T2 (hu) | 2022-01-28 |
| PL3394089T3 (pl) | 2022-01-17 |
| JP6771568B2 (ja) | 2020-10-21 |
| IL260182B1 (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2895256T3 (es) | Polipéptidos para inhibir la activación del complemento | |
| ES2281341T3 (es) | Lectina humana recombinante que se une a manano. | |
| Parente et al. | Complement factor H in host defense and immune evasion | |
| Du Clos | Pentraxins: structure, function, and role in inflammation | |
| Renner et al. | Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury | |
| US9540626B2 (en) | Regulator of complement activation and uses thereof | |
| S Laursen et al. | Structure, function and control of complement C5 and its proteolytic fragments | |
| US9649357B2 (en) | Treatment of chronic nephropathies using soluble complement receptor type I (sCR1) | |
| Hardy et al. | Soluble complement receptor 1 therapeutics | |
| JP6488376B2 (ja) | 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子を含む医薬組成物、薬剤および組み合わせ医薬 | |
| Zipfel et al. | ICW–2021 Virtual Workshop of the International Complement Society (ICS) | |
| Dinasarapu et al. | Complement factor H | |
| CN114929255A (zh) | DKK3b的肽模拟物及使用方法 | |
| Herpers | MBL and L-ficolin: levels and genotypes in community-acquired pneumonia | |
| Roumeninaa et al. | Molecular characterization and clinical history of a homozygous functional C1q abnormality | |
| Abe et al. | Complement in human disease | |
| Patil | Genome-wide identification of mammalian defensins and functional analysis of a novel defensin-related peptide | |
| Prinjha | Molecular cloning and sequence analysis of cDNAs encoding the transformation-sensitive actin cross-linking protein transgelin |